RÉSUMÉ
Diabetic retinopathy (DR) is a common complication of diabetes and leads to blindness. Anti-VEGF is a primary treatment for DR. Its therapeutic effect is limited in non- or poor responders despite frequent injections. By performing a comprehensive analysis of the semaphorins family, we identified the increased expression of Sema4D during oxygen-induced retinopathy (OIR) and streptozotocin (STZ)-induced retinopathy. The levels of soluble Sema4D (sSema4D) were significantly increased in the aqueous fluid of DR patients and correlated negatively with the success of anti-VEGF therapy during clinical follow-up. We found that Sema4D/PlexinB1 induced endothelial cell dysfunction via mDIA1, which was mediated through Src-dependent VE-cadherin dysfunction. Furthermore, genetic disruption of Sema4D/PlexinB1 or intravitreal injection of anti-Sema4D antibody reduced pericyte loss and vascular leakage in STZ model as well as alleviated neovascularization in OIR model. Moreover, anti-Sema4D had a therapeutic advantage over anti-VEGF on pericyte dysfunction. Anti-Sema4D and anti-VEGF also conferred a synergistic therapeutic effect in two DR models. Thus, this study indicates an alternative therapeutic strategy with anti-Sema4D to complement or improve the current treatment of DR.
Sujet(s)
Rétinopathie diabétique/traitement médicamenteux , Protéines de tissu nerveux/métabolisme , Récepteurs de surface cellulaire/métabolisme , Sémaphorines/métabolisme , Transduction du signal , Animaux , Antigènes CD , Diabète , Rétinopathie diabétique/induit chimiquement , Humains , Souris , Néovascularisation pathologiqueRÉSUMÉ
Angiogenesis is a crucial defense response to hypoxia that regulates the process of raising the promise of long-term neurologic recovery during the management of stroke. A high expression of antiangiogenic factors leads to the loss of neovascularization capacity in pathologic conditions. We have previously documented an impairment of the cerebral vessel perfusion and neovascularization in the cortex neighboring the stroke-induced lesion, which was accompanied by an activation of semaphorin 3E (Sema3E)/PlexinD1 after ischemic stroke. In this study, we employed micro-optical sectioning tomography to fully investigate the details of the vascular pattern, including the capillaries. We found that after transient middle cerebral artery occlusion, inhibiting PlexinD1 signaling led to an organized recovery of the vascular network in the ischemic area. We then further explored the possible mechanisms. In vivo, Sema3E substantially decreased dynamic delta-like 4 (DLL4) expression. In cultured brain microvascular endothelial cells, Sema3E down-regulated DLL4 expression via inhibiting Ras-related C3 botulinum toxin substrate 1-induced JNK phosphorylation. At the microcosmic level, Sema3E/PlexinD1 signaling promoted F-actin disassembly and focal adhesion reduction by activating the small guanosine triphosphatase Ras homolog family member J by releasing RhoGEF Tuba from direct binding to PlexinD1, thus mediating endothelial cell motility and filopodia retraction. Our study reveals that Sema3E/PlexinD1 signaling, which suppressed endothelial DLL4 expression, cell motility, and filopodia formation, is expected to be a novel druggable target for angiogenesis during poststroke progression.-Zhou, Y.-F., Chen, A.-Q., Wu, J.-H., Mao, L., Xia, Y.-P., Jin, H.-J., He, Q.-W., Miao, Q. R., Yue, Z.-Y., Liu, X.-L., Huang, M., Li, Y.-N., Hu, B. Sema3E/PlexinD1 signaling inhibits postischemic angiogenesis by regulating endothelial DLL4 and filopodia formation in a rat model of ischemic stroke.
Sujet(s)
Protéines et peptides de signalisation intracellulaire/métabolisme , Protéines membranaires/métabolisme , Protéines de tissu nerveux/métabolisme , Pseudopodes/métabolisme , Récepteurs de surface cellulaire/métabolisme , Sémaphorines/métabolisme , Animaux , Technique de Western , Encéphale/métabolisme , Encéphale/anatomopathologie , Encéphalopathie ischémique/génétique , Encéphalopathie ischémique/métabolisme , Encéphalopathie ischémique/anatomopathologie , Cellules cultivées , Cellules endothéliales/métabolisme , Technique d'immunofluorescence , Immunoprécipitation , Protéines et peptides de signalisation intracellulaire/génétique , Mâle , Protéines membranaires/génétique , Protéines de tissu nerveux/génétique , Phéochromocytome/métabolisme , Phéochromocytome/anatomopathologie , Pseudopodes/génétique , Rats , Rat Sprague-Dawley , Récepteurs de surface cellulaire/génétique , Sémaphorines/génétique , Accident vasculaire cérébral/génétique , Accident vasculaire cérébral/métabolisme , Accident vasculaire cérébral/anatomopathologieRÉSUMÉ
Whole-exome sequencing has been successful in identifying genetic factors contributing to familial or sporadic Parkinson's disease (PD). However, this approach has not been applied to explore the impact of de novo mutations on PD pathogenesis. Here, we sequenced the exomes of 39 early onset patients, their parents, and 20 unaffected siblings to investigate the effects of de novo mutations on PD. We identified 12 genes with de novo mutations (MAD1L1, NUP98, PPP2CB, PKMYT1, TRIM24, CEP131, CTTNBP2, NUS1, SMPD3, MGRN1, IFI35, and RUSC2), which could be functionally relevant to PD pathogenesis. Further analyses of two independent case-control cohorts (1,852 patients and 1,565 controls in one cohort and 3,237 patients and 2,858 controls in the other) revealed that NUS1 harbors significantly more rare nonsynonymous variants (P = 1.01E-5, odds ratio = 11.3) in PD patients than in controls. Functional studies in Drosophila demonstrated that the loss of NUS1 could reduce the climbing ability, dopamine level, and number of dopaminergic neurons in 30-day-old flies and could induce apoptosis in fly brain. Together, our data suggest that de novo mutations could contribute to early onset PD pathogenesis and identify NUS1 as a candidate gene for PD.
Sujet(s)
Encéphale/métabolisme , Neurones dopaminergiques/métabolisme , Mutation , Protéines de tissu nerveux/génétique , Maladie de Parkinson/génétique , Récepteurs de surface cellulaire/génétique , Adulte , Âge de début , Animaux , Apoptose/génétique , Translocateur nucléaire du récepteur des hydrocarbures aromatiques/antagonistes et inhibiteurs , Translocateur nucléaire du récepteur des hydrocarbures aromatiques/génétique , Translocateur nucléaire du récepteur des hydrocarbures aromatiques/métabolisme , Séquence nucléotidique , Encéphale/anatomopathologie , Études cas-témoins , Études de cohortes , Modèles animaux de maladie humaine , Dopamine/métabolisme , Neurones dopaminergiques/anatomopathologie , Protéines de Drosophila/antagonistes et inhibiteurs , Protéines de Drosophila/génétique , Protéines de Drosophila/métabolisme , Drosophila melanogaster/génétique , Drosophila melanogaster/métabolisme , Diagnostic précoce , Femelle , Expression des gènes , Réseaux de régulation génique , Humains , Mâle , Protéines de tissu nerveux/métabolisme , Parents , Maladie de Parkinson/diagnostic , Maladie de Parkinson/métabolisme , Maladie de Parkinson/anatomopathologie , Petit ARN interférent/génétique , Petit ARN interférent/métabolisme , Récepteurs de surface cellulaire/métabolisme , FratrieRÉSUMÉ
Brain tissue survival and functional recovery after ischemic stroke greatly depend on cerebral vessel perfusion and functional collateral circulation in the ischemic area. Semaphorin 3E (Sema3E), one of the class 3 secreted semaphorins, has been demonstrated to be a critical regulator in embryonic and postnatal vascular formation via binding to its receptor PlexinD1. However, whether Sema3E/PlexinD1 signaling is involved in poststroke neovascularization remains unknown. To determine the contribution of Sema3E/PlexinD1 signaling to poststroke recovery, aged rats (18 months) were subjected to a transient middle cerebral artery occlusion. We found that depletion of Sema3E/PlexinD1 signaling with lentivirus-mediated PlexinD1-specific-shRNA improves tissue survival and functional outcome. Sema3E/PlexinD1 inhibition not only increases cortical perfusion but also ameliorates blood-brain barrier damage, as determined by positron emission tomography and magnetic resonance imaging. Mechanistically, we demonstrated that Sema3E suppresses endothelial cell proliferation and angiogenic capacity. More importantly, Sema3E/PlexinD1 signaling inhibits recruitment of pericytes by decreasing production of platelet derived growth factor-BB in endothelial cells. Overall, our study revealed that inhibition of Sema3E/PlexinD1 signaling in the ischemic penumbra, which increases both endothelial angiogenic capacity and recruitment of pericytes, contributed to functional neovascularization and blood-brain barrier integrity in the aged rats. Our findings imply that Sema3E/PlexinD1 signaling is a novel therapeutic target for improving brain tissue survival and functional recovery after ischemic stroke.
Sujet(s)
Encéphalopathie ischémique/métabolisme , Encéphale/métabolisme , Protéines de tissu nerveux/métabolisme , Récepteurs de surface cellulaire/métabolisme , Sémaphorine-3A/métabolisme , Accident vasculaire cérébral/métabolisme , Animaux , Barrière hémato-encéphalique/anatomopathologie , Encéphale/anatomopathologie , Encéphalopathie ischémique/anatomopathologie , Mâle , Néovascularisation pathologique/physiopathologie , Neuropiline 1/antagonistes et inhibiteurs , Neuropiline 1/métabolisme , Rat Sprague-Dawley , Récupération fonctionnelle , Sémaphorine-3A/antagonistes et inhibiteurs , Transduction du signal , Accident vasculaire cérébral/anatomopathologie , Régulation positiveRÉSUMÉ
Blood-brain barrier (BBB) disruption plays a critical role in brain injury induced by cerebral ischemia, and preserving BBB integrity during ischemia could alleviate cerebral injury. We examined the role of miR-130a in ischemic BBB disruption by using models of rat middle cerebral artery occlusion and cell oxygen-glucose deprivation. We found that ischemia significantly increased microRNA-130a (miR-130a) level and that miR-130a was predominantly from brain microvascular endothelial cells. Antagomir-130a, an antagonist of miR-130a, could attenuate brain edema, lower BBB permeability, reduce infarct volume, and improve neurologic function. MiR-130a overexpression induced by miR-130a mimic increased monolayer permeability, and intercellular inhibition of miR-130a by a miR-130a inhibitor suppressed oxygen-glucose deprivation-induced increase in monolayer permeability. Moreover, dual luciferase reporter system showed that Homeobox A5 was the direct target of miR-130a. MiR-130a, by inhibiting Homeobox A5 expression, could down-regulate occludin, thereby increasing BBB permeability. Our results suggested that miR-130a might be implicated in ischemia-induced BBB dysfunction and serve as a target for the treatment of ischemic stroke.-Wang, Y., Wang, M.-D., Xia, Y.-P., Gao, Y., Zhu, Y.-Y., Chen, S.-C., Mao, L., He, Q.-W., Yue, Z.-Y., Hu, B. MicroRNA-130a regulates cerebral ischemia-induced blood-brain barrier permeability by targeting Homeobox A5.
Sujet(s)
Barrière hémato-encéphalique/métabolisme , Encéphalopathie ischémique/métabolisme , Protéines à homéodomaine/métabolisme , microARN/métabolisme , Occludine/biosynthèse , Animaux , Barrière hémato-encéphalique/anatomopathologie , Encéphalopathie ischémique/génétique , Encéphalopathie ischémique/anatomopathologie , Protéines à homéodomaine/génétique , Mâle , microARN/antagonistes et inhibiteurs , microARN/génétique , Occludine/génétique , Oligonucléotides/pharmacologie , Perméabilité , Rats , Rat Sprague-DawleyRÉSUMÉ
Fluoxetine, one of the selective serotonin reuptake inhibitor (SSRI) antidepressants, has been thought to be effective for treating post-stroke depression (PSD). Recent work has shown that fluoxetine may exert an antidepressive effect through increasing the level of brain-derived neurotrophic factor (BDNF), but the underlying mechanism still remains unclear. In the present study, we successfully established the PSD model using male C57BL/6 J mice by photothrombosis of the left anterior cortex combined with isolatied-housing conditions. In the process, we confirmed that fluoxetine could improve the depression-like behaviors of PSD mice and upregulate the expression of BDNF in the hippocampus. However, depletion of BDNF by transfecting lentivirus-derived shBDNF in hippocampus suppressed the effect of fluoxetine. Furthermore, we demonstrated the epigenetic mechanisms involved in regulation of BDNF expression induced by fluoxetine. We found a statistically significant increase in DNA methylation at specific CpG sites (loci 2) of Bdnf promoter IV in the hippocampus of PSD mice. We also found that fluoxetine treatment could disassociate the MeCP2-CREB-Bdnf promoter IV complex via phosphorylation of MeCP2 at Ser421 by Protein Kinase A (PKA). Our research highlighted the importance of fluoxetine in regulating BDNF expression which could represent a potential strategy for preventing PSD.
Sujet(s)
Antidépresseurs de seconde génération/usage thérapeutique , Facteur neurotrophique dérivé du cerveau/génétique , Dépression/traitement médicamenteux , Dépression/étiologie , Épigenèse génétique/effets des médicaments et des substances chimiques , Fluoxétine/usage thérapeutique , Accident vasculaire cérébral/complications , Animaux , Antidépresseurs de seconde génération/pharmacologie , Dépression/génétique , Trouble dépressif/traitement médicamenteux , Trouble dépressif/étiologie , Trouble dépressif/génétique , Modèles animaux de maladie humaine , Fluoxétine/pharmacologie , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , Mâle , Souris de lignée C57BL , Activation de la transcription/effets des médicaments et des substances chimiquesRÉSUMÉ
INTRODUCTION: Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most prevalent cause of familial and sporadic Parkinson's disease (PD). Because most pathogenic LRRK2 mutations result in enhanced kinase activity, it suggests that LRRK2 inhibitors may serve as a potential treatment for PD. To evaluate whether LRRK2 inhibitors are effective therapies for PD, it is crucial to know whether LRRK2 inhibitors will affect dopaminergic (DAergic) neurotransmission. However, to date, there is no study to investigate the impact of LRRK2 inhibitors on DAergic neurotransmission. AIMS: To address this gap in knowledge, we examined the effects of three types of LRRK2 inhibitors (LRRK2-IN-1, GSK2578215A, and GNE-7915) on dopamine (DA) release in the dorsal striatum using fast-scan cyclic voltammetry and DA neuron firing in the substantia nigra pars compacta (SNpc) using patch clamp in mouse brain slices. RESULTS: We found that LRRK2-IN-1 at a concentration higher than 1 µM causes off-target effects and decreases DA release, whereas GSK2578215A and GNE-7915 do not. All three inhibitors at 1 µM have no effect on DA release and DA neuron firing rate. We have further assessed the effects of the inhibitors in two preclinical LRRK2 mouse models (i.e., BAC transgenic hG2019S and hR1441G) and demonstrated that GNE-7915 enhances DA release and synaptic vesicle mobilization/recycling. CONCLUSION: GNE-7915 can be validated for further therapeutic development for PD.
Sujet(s)
Corps strié/cytologie , Dopamine/métabolisme , Leucine-rich repeat serine-threonine protein kinase-2/métabolisme , Maladie de Parkinson/anatomopathologie , Substantia nigra/cytologie , Aminopyridines/pharmacologie , Animaux , Benzamides/pharmacologie , Benzodiazépinones/pharmacologie , Phénomènes biophysiques/effets des médicaments et des substances chimiques , Phénomènes biophysiques/génétique , Corps strié/effets des médicaments et des substances chimiques , Modèles animaux de maladie humaine , Relation dose-effet des médicaments , Stimulation électrique , Techniques in vitro , Leucine-rich repeat serine-threonine protein kinase-2/génétique , Mâle , Souris , Souris transgéniques , Morpholines/pharmacologie , Mutation/génétique , Maladie de Parkinson/traitement médicamenteux , Maladie de Parkinson/génétique , Techniques de patch-clamp , Pyrimidines/pharmacologie , Substantia nigra/effets des médicaments et des substances chimiquesRÉSUMÉ
Autophagy is a cell self-digestion process via lysosomes that clears "cellular waste", including aberrantly modified proteins or protein aggregates and damaged organelles. Therefore, autophagy is considered a protein and organelle quality control mechanism that maintains normal cellular homeostasis. Dysfunctional autophagy has been observed in ageing tissues and several ageing-associated diseases. Lifespan of model organisms such as yeast, worms, flies, and mice can be extended through promoting autophagy, either by genetic manipulations such as over-expression of Sirtuin 1, or by administrations of rapamycin, resveratrol or spermidine. The evidence supports that autophagy may play an important role in delaying ageing or extending lifespan. In this review, we summarize the current knowledge about autophagy and its regulation, outline recent developments ie the genetic and pharmacological manipulations of autophagy that affects the lifespan, and discuss the role of autophagy in the ageing-related diseases.
Sujet(s)
Vieillissement , Autophagie , Tumeurs/anatomopathologie , Maladies neurodégénératives/anatomopathologie , Vieillissement/effets des médicaments et des substances chimiques , Animaux , Autophagie/effets des médicaments et des substances chimiques , Découverte de médicament , Humains , Tumeurs/traitement médicamenteux , Tumeurs/métabolisme , Maladies neurodégénératives/traitement médicamenteux , Maladies neurodégénératives/métabolismeRÉSUMÉ
OBJECTIVE: Over the past decades, many studies have used data mining technology to predict the 5-year survival rate of colorectal cancer, but there have been few reports that compared multiple data mining algorithms to the TNM classification of malignant tumors (TNM) staging system using a dataset in which the training and testing data were from different sources. Here we compared nine data mining algorithms to the TNM staging system for colorectal survival analysis. METHODS: Two different datasets were used: 1) the National Cancer Institute's Surveillance, Epidemiology, and End Results dataset; and 2) the dataset from a single Chinese institution. An optimization and prediction system based on nine data mining algorithms as well as two variable selection methods was implemented. The TNM staging system was based on the 7(th) edition of the American Joint Committee on Cancer TNM staging system. RESULTS: When the training and testing data were from the same sources, all algorithms had slight advantages over the TNM staging system in predictive accuracy. When the data were from different sources, only four algorithms (logistic regression, general regression neural network, bayesian networks, and Naïve Bayes) had slight advantages over the TNM staging system. Also, there was no significant differences among all the algorithms (p>0.05). CONCLUSIONS: The TNM staging system is simple and practical at present, and data mining methods are not accurate enough to replace the TNM staging system for colorectal cancer survival prediction. Furthermore, there were no significant differences in the predictive accuracy of all the algorithms when the data were from different sources. Building a larger dataset that includes more variables may be important for furthering predictive accuracy.
Sujet(s)
Algorithmes , Tumeurs colorectales/diagnostic , Tumeurs colorectales/anatomopathologie , Fouille de données/méthodes , Stadification tumorale/méthodes , Bases de données factuelles , Femelle , Études de suivi , Humains , Mâle , Pronostic , Courbe ROC , Analyse de survieRÉSUMÉ
Accumulation of α-synuclein (α-Syn) is a common pathology for both familiar and sporadic Parkinson's disease (PD), enhancing its clearance might be a promising strategy for treating PD. To assess the potential of trehalose in this regard, we investigated its effect on the PC12 cells overexpressing wild type (WT) or A53T mutant α-Syn and the implicated pathway it might mediated. We observed that trehalose promoted the clearance of A53T α-Syn but not WT α-Syn in PC12 cells, and confirmed the increased LC3 and Lysotracker RED positive autolysosomes by using lysotracker and LC3 staining, the enhanced expression of LC3-II in Western blot, and more autophagosomes under Transmission Electron Microscope in a dose dependent manner after the trehalose treatment. The activation of autophagy can be alleviated by applying macroautophagy inhibitor 3-methyladenine (3-MA). In addition, degradation of A53T and WT α-Syn was blocked after Ubiquitin Proteasome System (UPS) inhibitor (MG132) was applied in those PC12 cells overexpressing A53T or WT α-Syn, suggesting that A53T α-Syn could be degraded by both UPS and macroautophagy. But the effect of trehalose on A53T α-Syn is mainly mediated through the macroautophagy pathway, which is not a dominant way for WT α-Syn clearance. Further in vivo research will be needed to verify the effectiveness of trehalose in treating PD.
Sujet(s)
Mutation ponctuelle , Tréhalose/pharmacologie , alpha-Synucléine/biosynthèse , alpha-Synucléine/génétique , Adénine/analogues et dérivés , Adénine/pharmacologie , Alanine , Animaux , Autophagie/effets des médicaments et des substances chimiques , Technique de Western , Survie cellulaire/effets des médicaments et des substances chimiques , Relation dose-effet des médicaments , Technique d'immunofluorescence , Lysosomes/métabolisme , Microscopie électronique à transmission , Cellules PC12 , Phagosomes/métabolisme , Inhibiteurs des phosphoinositide-3 kinases , Inhibiteurs du protéasome/pharmacologie , Rats , Transduction du signal/effets des médicaments et des substances chimiques , Sels de tétrazolium , Thiazoles , Thréonine , Transduction génétique , Régulation positiveRÉSUMÉ
The aggregation of alpha-synuclein (AS) is pivotally implicated in the development of Parkinson's disease (PD), inhibiting this process might be effective in treating PD. Here, by using circular dichroism spectroscopy, thioflavin T fluorescence, and atomic force microscopy, we found that trehalose at low concentration disaggregates preformed A53T AS protofibrils and fibrils into small aggregates or even random coil structure, while trehalose at high concentration slows down the structural transition into ß-sheet structure and completely prevents the formation of mature A53T AS fibrils. Further work in vivo will be needed to evaluate its potential as a novel strategy for treating PD.
Sujet(s)
Protéines mutantes/composition chimique , Mutation , Multimérisation de protéines/effets des médicaments et des substances chimiques , Tréhalose/pharmacologie , alpha-Synucléine/composition chimique , Humains , Modèles moléculaires , Protéines mutantes/génétique , Structure secondaire des protéines/effets des médicaments et des substances chimiques , alpha-Synucléine/génétiqueRÉSUMÉ
BACKGROUND: Human heparanase plays an important role in cancer development and single nucleotide polymorphisms (SNPs) in the heparanase gene (HPSE) have been shown to be correlated with gastric cancer. The present study examined the associations between individual SNPs or haplotypes in HPSE and susceptibility, clinicopathological parameters and prognosis of gastric cancer in a large sample of the Han population in northern China. METHODOLOGY/PRINCIPAL FINDINGS: Genomic DNA was extracted from formalin-fixed, paraffin-embedded normal gastric tissue samples from 404 patients and from blood from 404 healthy controls. Six SNPs were genotyped by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. A chi-square (χ2) test and unconditional logistic regression were used to analyze the risk of gastric cancer; a Log-rank test and Cox proportional hazards model were used to produce survival analysis and a Kaplan-Meier method was used to map survival curves. The mean genotyping success rates were more than 99% in both groups. Haplotype CA in the block composed of rs11099592 and rs4693608 had a greater distribution in the group of Borrmann types 3 and 4 (Pâ=â0.037), the group of a greater number of lymph node metastases (N3 vs N0 group, Pâ=â0.046), and moreover was correlated to poor survival (CG vs CA: HRâ=â0.645, 95%CI: 0.421-0.989, Pâ=â0.044). In addition, genotypes rs4693608 AA and rs4364254 TT were associated with poor survival (Pâ=â0.030, HRâ=â1.527, 95%CI: 1.042-2.238 for rs4693608 AA; Pâ=â0.013, HRâ=â1.546, 95%CI: 1.096-2.181 for rs4364254 TT). There were no correlations between individual SNPs or haplotypes and gastric cancer risk. CONCLUSIONS/SIGNIFICANCE: A functional haplotype in HPSE was found, which included the important SNP rs4693608. SNPs in HPSE play an important role in gastric cancer progression and survival, and perhaps may be a molecular marker for prognosis and treatment values.
Sujet(s)
Glucuronidase/génétique , Haplotypes/génétique , Tumeurs de l'estomac/génétique , Adulte , Sujet âgé , Asiatiques/génétique , Femelle , Prédisposition génétique à une maladie/génétique , Humains , Mâle , Adulte d'âge moyen , Polymorphisme de nucléotide simple/génétiqueRÉSUMÉ
BACKGROUND: MicroRNAs (miRNAs) are involved in cancer development and progression, acting as tumor suppressors or oncogenes. Our previous studies have revealed that miR-148a and miR-152 are significantly down-regulated in gastrointestinal cancers. Interestingly, miR-148b has the same "seed sequences" as miR-148a and miR-152. Although aberrant expression of miR-148b has been observed in several types of cancer, its pathophysiologic role and relevance to tumorigenesis are still largely unknown. The purpose of this study was to elucidate the molecular mechanisms by which miR-148b acts as a tumor suppressor in gastric cancer. RESULTS: We showed significant down-regulation of miR-148b in 106 gastric cancer tissues and four gastric cancer cell lines, compared with their non-tumor counterparts by real-time RT-PCR. In situ hybridization of ten cases confirmed an overt decrease in the level of miR-148b in gastric cancer tissues. Moreover, the expression of miR-148b was demonstrated to be associated with tumor size (P = 0.027) by a Mann-Whitney U test. We also found that miR-148b could inhibit cell proliferation in vitro by MTT assay, growth curves and an anchorage-independent growth assay in MGC-803, SGC-7901, BGC-823 and AGS cells. An experiment in nude mice revealed that miR-148b could suppress tumorigenicity in vivo. Using a luciferase activity assay and western blot, CCKBR was identified as a target of miR-148b in cells. Moreover, an obvious inverse correlation was observed between the expression of CCKBR protein and miR-148b in 49 pairs of tissues (P = 0.002, Spearman's correlation). CONCLUSIONS: These findings provide important evidence that miR-148b targets CCKBR and is significant in suppressing gastric cancer cell growth. Maybe miR-148b would become a potential biomarker and therapeutic target against gastric cancer.
Sujet(s)
Marqueurs biologiques tumoraux/biosynthèse , Prolifération cellulaire , Gènes suppresseurs de tumeur , microARN/biosynthèse , Tumeurs de l'estomac/métabolisme , Animaux , Marqueurs biologiques tumoraux/génétique , Études cas-témoins , Lignée cellulaire tumorale , Régulation négative , Femelle , Gènes rapporteurs , Humains , Souris , Souris de lignée BALB C , Souris nude , microARN/génétique , Transplantation tumorale , Récepteur de la cholécystokinine de type B/biosynthèse , Récepteur de la cholécystokinine de type B/génétique , Tumeurs de l'estomac/anatomopathologie , Charge tumoraleRÉSUMÉ
BACKGROUND: This study aimed to evaluate the prognostic impact of pT2 subclassification according to the depth of muscularis propria (MP) invasion and to explore the clinicopathologic factors correlated with lymph node metastasis (LNM) and postoperative hematogenous metastasis in pT2 colorectal cancer. METHODS: A total of 317 patients with pT2 colorectal cancer were reviewed. pT2a represents the infiltration of the inner circumferential layer of the MP, and pT2b represents the infiltration of the outer longitudinal layer of the MP. Clinicopathologic factors and overall survival rates were compared in patients with pT2a and pT2b stage cancers. Multivariate analysis was performed to identify the significantly important prognostic factors. Univariate and multivariate analyses were performed, respectively, to identify the significantly important clinicopathologic factors correlated with LNM and postoperative hematogenous metastasis in pT2 colorectal cancer. RESULTS: According to the depth of MP invasion, 107 patients were classified as pT2a and 210 patients were classified as pT2b. Among them, there were 55 patients with LNM, 34 patients with postoperative hematogenous metastasis. There was significant difference in most of clinicopathologic features between patients in the pT2a and pT2b stages. Multivariate analysis identified pN stage (P < .001) and tumor location (P = .036) were independent factors affecting the prognosis. However, no apparent difference was observed between pT2a versus pT2b cancer. Univariate and multivariate analyses uniformly identified lymphovascular invasion (P = .035) and the depth of MP invasion (P = .005) as significantly correlated with LNM. Multivariate analysis found tumor location (P = .021) and the presence or absence of LNM (P < .001) were important factors affecting postoperative hematogenous metastasis. CONCLUSIONS: In pT2 colorectal cancer treated with R0 surgery, there is a high risk of LNM in deep MP invasion versus superficial MP invasion. The pT2 subclassification system had no significant advantage in identifying a different prognosis, except for predicting the LNM before surgery. Rectal cancer and the presence of LNM were high-risk factors resulting in hematogenous metastasis postoperatively.